Detecting and predicting neutralization of alemtuzumab responses in MS.
Gauri SaxenaJames M MooreMeleri JonesGareth PryceLiaqat AliGeorgia R LeisegangVivek VijaySamantha LovelessNeil P RobertsonKlaus SchmiererGavin GiovannoniSharmilee GnananpavanDavid BakerEmma C TallantyreAngray S KangPublished in: Neurology(R) neuroimmunology & neuroinflammation (2020)
Although ADAs to alemtuzumab have been portrayed as being of no clinical significance, alemtuzumab-specific antibodies appear to be clinically relevant for some individuals, although causation remains to be established. Monitoring of lymphocyte depletion and the antidrug response may be of practical value in patients requiring additional cycles of alemtuzumab. ADA detection may help to inform on retreatment or switching to another treatment.